Clinical Trial Update: CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) [Phase 1]

View source ↗

Summary

Phase 1 study of CD5789 in early cutaneous T-cell lymphoma (CTCL) has completed its Phase 1 portion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• CD5789

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 1 | Status: COMPLETED